What are the risks and management strategies for using D5W (5% dextrose in water) in a patient undergoing Continuous Veno-Venous Hemodiafiltration (CVVHDF) with hyponatremia overcorrection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

D5W Administration During CVVHDF for Hyponatremia Overcorrection

Primary Recommendation

D5W (5% dextrose in water) infused prefilter is a safe and effective strategy to prevent or reverse overcorrection of hyponatremia in patients undergoing CVVHDF, with the infusion rate calculated to achieve a target sodium correction of ≤6-8 mEq/L per 24 hours. 1, 2

Understanding the Clinical Problem

Why Overcorrection Occurs During CVVHDF

  • Standard CVVHDF replacement and dialysate fluids contain physiologic sodium concentrations (typically 140 mEq/L), which can cause excessively rapid sodium correction in severely hyponatremic patients 3, 2
  • The high effluent volumes required for adequate solute clearance (20-25 mL/kg/hr minimum) accelerate sodium correction beyond safe limits 1
  • Patients with severe hyponatremia (<126 mEq/L) and acute kidney injury requiring CRRT are at highest risk for osmotic demyelination syndrome (ODS) if sodium rises >8 mEq/L in 24 hours 4, 1, 2

Critical Risk of Osmotic Demyelination Syndrome

  • Overcorrection exceeding 8 mmol/L in 24 hours can cause ODS, presenting with dysarthria, dysphagia, oculomotor dysfunction, and quadriparesis typically 2-7 days after rapid correction 4
  • Patients with advanced liver disease, alcoholism, malnutrition, or severe hyponatremia require even more cautious correction (4-6 mEq/L per day maximum) 4

The D5W Prefilter Strategy: Step-by-Step Approach

1. Initial Assessment and Target Setting

  • Measure baseline serum sodium and establish target correction rate: ≤6 mEq/L per 24 hours for standard-risk patients, ≤4-6 mEq/L per 24 hours for high-risk patients (cirrhosis, alcoholism, malnutrition) 4, 1, 2
  • Calculate the patient's weight in kg to determine appropriate CVVHDF effluent dose 1
  • Verify that standard isotonic replacement/dialysate fluids would cause excessive correction before implementing D5W strategy 1, 2

2. D5W Infusion Rate Calculation

  • Use a simplified equation to determine D5W rate based on prescribed effluent volume 1
  • The D5W is infused prefilter as pre-blood pump to dilute the effective sodium concentration of the CVVHDF circuit 1
  • In the case series, calculated amounts of D5W prevented sodium correction from exceeding 8 mEq/day while maintaining recommended effluent volumes of 20-25 mL/kg/hr 1

3. Practical Implementation

  • Infuse D5W through a separate line into the arterial (pre-filter) limb of the CVVHDF circuit 1
  • Continue standard isotonic replacement and dialysate fluids at prescribed rates 1, 2
  • The D5W effectively reduces the sodium concentration of the combined fluid entering the patient 1

4. Alternative Approach: Modified Low-Sodium Fluids

  • If D5W prefilter is not feasible, prepare custom low-sodium dialysate and replacement fluids (119-126 mEq/L sodium) 5, 2, 6
  • This approach requires pharmacy preparation of individualized solutions adjusted daily based on serum sodium levels 5, 6
  • In one series, low-sodium CVVHDF (119-126 mEq/L) achieved mean sodium increases of only 3 mEq/L at 24 hours and 3 mEq/L at 48 hours, with no cases of ODS 2

Monitoring Protocol

Frequency of Sodium Checks

  • Check serum sodium every 2-4 hours during the first 24 hours of CVVHDF with D5W strategy 4, 1
  • After initial stabilization, check every 4-6 hours until target sodium range achieved 4
  • Continue monitoring every 6-12 hours once stable correction rate established 4

Adjusting D5W Rate

  • If sodium correction exceeds 6 mEq/L in any 24-hour period, increase D5W infusion rate to slow correction 1
  • If sodium correction is inadequate (<2 mEq/L per 24 hours in severely symptomatic patients), decrease D5W rate 1
  • The D5W rate can be adjusted dynamically without changing the CVVHDF prescription 1

Managing Overcorrection That Has Already Occurred

  • If sodium has already been overcorrected (>8 mEq/L in 24 hours), immediately increase D5W infusion rate to reverse the rise 4, 1
  • Consider adding desmopressin to promote water retention and lower sodium 4
  • In the case series, adding calculated amounts of D5W successfully decreased sodium levels back down to prevent ODS risk even after initial overcorrection 1

Evidence Quality and Clinical Outcomes

Safety Data

  • In a case series of 4 patients using D5W prefilter, none exceeded 8 mEq/day sodium correction, and overcorrection was successfully reversed when it occurred 1
  • In 19 patients treated with low-sodium CVVHDF (119-126 mEq/L fluids), only 2 (11%) had sodium increase >6 mEq/L at 24 hours, and zero patients developed ODS 2
  • Two liver transplant patients with severe hyponatremia (121-122 mmol/L) underwent transplant with sodium-reduced CVVHDF and had controlled correction without neurological deficits 6

Effectiveness for Maintaining Adequate Clearance

  • The D5W prefilter strategy allows delivery of recommended effluent volumes of 20-25 mL/kg/hr for adequate solute clearance while preventing overcorrection 1
  • This is critical because simply reducing effluent volume to slow sodium correction may be inadequate for managing other metabolic derangements (hyperammonemia, acidosis, uremia) 3, 1

Special Populations and Considerations

Patients with Cirrhosis or Liver Failure

  • These patients require maximum correction of 4-6 mEq/L per day due to extremely high ODS risk 4, 6
  • Albumin infusion may be beneficial alongside controlled sodium correction 4
  • Avoid hypertonic saline unless life-threatening symptoms present, as it worsens ascites and edema 4

Patients with Severe Symptomatic Hyponatremia

  • If patient has seizures, altered mental status, or coma from acute hyponatremia (<48 hours onset), initial rapid correction of 6 mEq/L over 6 hours with 3% saline may be appropriate before initiating CVVHDF 4
  • Once symptoms resolve, transition to controlled correction with D5W-modified CVVHDF to prevent total 24-hour correction from exceeding 8 mEq/L 4, 1

Pediatric Patients

  • Hypotonic fluids including D5W can cause hospital-acquired hyponatremia in 15-30% of hospitalized children when used as maintenance fluids 7
  • However, in the specific context of preventing overcorrection during CVVHDF, D5W prefilter serves a therapeutic purpose distinct from maintenance hydration 1
  • Monitor glucose levels closely, as supra-physiologic glucose concentrations can cause hyperglycemia 3

Common Pitfalls and How to Avoid Them

Pitfall 1: Using Standard CVVHDF Fluids Without Modification

  • Never initiate CVVHDF with standard isotonic fluids (140 mEq/L sodium) in patients with severe hyponatremia (<126 mEq/L) without a plan to prevent overcorrection 1, 2
  • The default approach will cause rapid, uncontrolled sodium rise 2

Pitfall 2: Inadequate Monitoring Frequency

  • Checking sodium only once or twice daily is insufficient during active correction 4, 1
  • Check every 2-4 hours initially to detect and respond to overcorrection before irreversible damage occurs 4, 1

Pitfall 3: Reducing Effluent Volume to Slow Correction

  • While reducing CVVHDF dose may slow sodium correction, it compromises clearance of other toxins (ammonia, uremic solutes, acid) 3, 1
  • The D5W prefilter strategy allows full-dose CVVHDF (20-25 mL/kg/hr) while controlling sodium correction 1

Pitfall 4: Failing to Recognize High-Risk Patients

  • Patients with cirrhosis, chronic alcoholism, malnutrition, or baseline sodium <120 mEq/L require maximum 4-6 mEq/L correction per day, not the standard 8 mEq/L 4
  • Adjust D5W infusion rate accordingly for these patients 1

Pitfall 5: Ignoring Glucose Management

  • D5W infusion can cause hyperglycemia, particularly at high infusion rates 3
  • Monitor blood glucose and adjust insulin as needed, but do not discontinue D5W solely for glucose control if it is preventing life-threatening overcorrection 3

Alternative Strategies When D5W Prefilter Not Available

Custom Low-Sodium Replacement/Dialysate Fluids

  • Prepare individualized solutions with sodium content 10-15 mEq/L below patient's current serum sodium 5, 2, 6
  • Adjust sodium concentration daily based on measured levels 5, 6
  • This requires pharmacy capability to compound custom solutions 5, 2

Bicarbonate-Based Buffer Preference

  • Use bicarbonate rather than lactate as buffer in CVVHDF fluids for patients with liver failure or lactic acidosis 3
  • Lactate-based solutions can worsen acidosis in these populations 3

Key Takeaway Algorithm

  1. Patient with severe hyponatremia (<126 mEq/L) requires CVVHDF → High risk for overcorrection with standard fluids 1, 2

  2. Calculate target sodium correction rate:

    • Standard risk: ≤6-8 mEq/L per 24 hours 4, 1
    • High risk (cirrhosis, alcoholism, malnutrition): ≤4-6 mEq/L per 24 hours 4

  3. Implement D5W prefilter strategy:

    • Infuse calculated D5W rate into arterial limb of CVVHDF circuit 1
    • Maintain standard CVVHDF prescription (20-25 mL/kg/hr effluent) 1

  4. Monitor serum sodium every 2-4 hours initially 4, 1

  5. Adjust D5W rate dynamically based on measured correction rate 1

  6. If overcorrection occurs (>8 mEq/L in 24 hours):

    • Increase D5W rate immediately 1
    • Consider desmopressin 4
    • Watch for ODS symptoms over next 2-7 days 4

References

3
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

4
Guideline

Management of Sodium Imbalance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5
Research

Safe correction of severe hyponatremia in patient with severe renal failure using continuous venovenous hemofiltration with modified sodium content in the replacement fluid.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2018

7
Guideline

D5W-Induced Hyponatremia: Clinical Context and Prevention

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the recommendations for starting Continuous Renal Replacement Therapy (CRRT) in a patient with hyponatremia and a sodium level of 122 mEq/L when only a CRRT bath with a sodium concentration of 140 mEq/L is available?
Do you use pre-filter or post-filter D5W (Dextrose 5% in Water) for a patient with hyponatremia on Continuous Renal Replacement Therapy (CRRT)?
Should the normal saline IV infusion be slowed down or held in a hyponatremic patient with a rising sodium level?
What is the recommended drip rate for a sodium bicarbonate (NaHCO3) infusion in patients requiring bicarbonate therapy?
Should fluids be held or D5W (Dextrose 5% in Water) be given in a hypovolemic hyponatremia patient with improving sodium levels?
What are the appropriate treatment options for a patient with hyperhydrosis (excessive sweating)?
Can a supervaccine be administered to a patient who received an influenza (flu) vaccination 2 months ago?
Can a patient with severe anemia (hemoglobin level of 7.6 g/dL) and a history of cancer receive a blood transfusion and chemotherapy on the same day?
What alternative treatment options are available for a patient with obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) who has a history of not tolerating bupropion and Viibryd (vilazodone), and has a GeneSight report indicating that escitalopram is also not recommended?
What is the appropriate management for a patient with laboratory results indicating hyperthyroidism?
What is the significance of staging in a patient with colon cancer, particularly in determining the need for adjuvant chemotherapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question